5 billion antibacterial drug eye dosage form first imitation competition fierce this Wuhan pharmaceutical company new entry.

Pharmaceutical Network August 14th, August 12th, the latest CDE data show that Wuhan Noan Pharmaceuticals' hydrochloric acid Moxisa star eye drops 4 types of imitation listing applications were approved.
only Ercon has been approved for import in the domestic market, with the product entering the Chinese market in 2018 and the National Health Insurance Directory in 2019.
figure 1: Wuhan Noan Pharmaceuticals' registration of hydrochloric acid Moxisa Star eye drops Source: CDE official website Moxishaxing is a body-wide anti-bacterial drug heavy variety, Minanet data show that in 2019 in China's urban public hospitals, county-level public hospitals, urban community centers and township hospitals (referred to as China's public medical institutions) terminal sales of more than 5 billion yuan, of which injections accounted for more than 80%, eye preparations accounted for only 0.02%.
, the world's largest ophthalmology company, was a subsidiary of Novarian, completing acquisitions between 2011 and 2012 and parting ways in 2019.
The company's hydrochloric acid moxisa star eye drops can be used to treat bacterial conjunctivitis caused by sensitive microorganisms in all populations, the product was included in the priority review in November 2017, was approved for entry into the Chinese market in 2018, is currently the first priority review of antibiotic eye drops, is currently the world's only can be used for newborns (over 0 years old) antibiotic eye drops.
the current domestic market only the original research products approved for import, in 2019 into the national health insurance directory, for category B varieties.
Figure 2: Medical insurance situation of hydrochloric acid Moxisha star drops Source: Minet China Health Insurance Directory Database MED2.0 China Drug Review Database data show that, in addition to Wuhan Noan Pharmaceuticals, Qilu, Koren, Yangzijiang, Xingqi eye medicine, China Resources Zizhu Pharmaceuticals and other 10 pharmaceutical companies, 4 types of imitation listing applications are in the review and approval, the first imitation of the fierce competition.
It is worth noting that the third round of the national collection catalog for the first time included eye drops - left oxyfluorosa star eye drops, the original research and ginseng tian pharmaceutical will be approved according to the new classification of the same evaluation of Yangzijiang and Zhongshan Wanhan pharmaceutical price war.
, the importance of eye drops in clinical use is becoming more and more prominent, the market activity of eye preparations will continue to climb.
: CDE official website, Minet database review data statistics as of August 13, 2020, if there are errors, please point out.
.